HEPA
Hepion Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.10
−1.45%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +65.5%
- EBIT
- +63.8%
- EPS
- +99.5%
- Free cash flow
- +74.1%
- Operating cash flow
- +74.1%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- —
- EBITDA
- +74.9%
- EBIT
- +78.5%
- Net income
- +37.3%
- EPS
- +99.2%
- Free cash flow
- +82.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026